Nanoparticles Mimic Exosomes and Attenuate Growth Factor-Induced Cell Migration in Melanoma Cells
Benjamin Paul Gallant,Matthew Clark,Audrey Madigan,Yinsheng Wan,Wei Zhang,Hongguang Lu
DOI: https://doi.org/10.1096/fasebj.31.1_supplement.614.17
2017-01-01
Abstract:Melanoma is notoriously aggressive and still considered untreatable, in spite of some of the most recent breakthroughs related to immunotherapy. Our previous studies have shown that melanoma cells, compared to untransformed normal human melanocytes, exhibit constitutive mTOR activity and are resistant to oxidative stress. Exosomes, which are membranous vesicles of various sizes between 30–100 nm, are recently being intensively studied. These exosomes are involved in cell‐cell communications and aggression of cancer cells. We hypothesized that constitutive mTOR activity in melanoma cells is attributable to biogenesis and release of exosomes, resulting in the aggression and metastatic potential of melanoma. Externally applied nanoparticles with similar sizes to exosomes may confuse melanoma cells and thus have biological effects or therapeutic benefits. Using phagokinetic motility assay, we observed that gold and iron nanoparticles (50 nm.) attenuated serum‐induced cell migration in cultured melanoma cells (WM 266‐4 cells), similarly, inhibitors of PI3K/AKT, MEK/ERK, Na + /Ca ++ Channels and mTOR showed inhibitory effects. Confocal microscopy results showed that while above inhibitors decreased mTOR activity in melanoma cells, gold and iron nanoparticles also minimally inhibit serum‐induced mTOR activity (expressed in phosphorylation of ribosomal protein S6), and MEK/ERK activity, which are critical for cell migration. Western blot analysis demonstrated that serum induced biogenesis and release of exosomes, as expressed by two of the markers, CD63 and Mart1, which were minimally inhibited by inhibitors of PI3K/AKT, MEK/ERK, and mTOR. Furthermore, when WM 266‐4 were treated with known inhibitors of exosomes, Monensin and Brefeldin A, serum‐induced mTOR activity (expressed in phosphorylation of ribosomal protein S6) and cell migration (phagokinetic motility track assay) were markedly reduced. Together, our data indicate that nanoparticles, mimicking exosomes, inhibit mTOR, resulting in the attenuation of cell migration of melanoma cells. Additionally, our data also suggests that inhibitors of these exosomes greatly reduce cell migration and mTOR activity in these melanoma cells. Our results suggest that nanoparticles with similar sizes to exosomes, and inhibitors of these exosomes, may provide therapeutic benefits to melanoma treatment. Support or Funding Information RI‐INBRE